Innovent and IASO Bio Present Updated Long-Term Follow-Up Data for BCMA CAR-T FUCASO® (Equecabtagene Autoleucel) at IMS 2023

/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...

Related Keywords

Hong Kong ,Tongji ,Sichuan ,China ,Taiwan ,United States ,Macau ,Huazhong ,Hubei ,Suzhou ,Jiangsu ,Chinese ,Lugui Qiu ,Eli Lilly ,Innovent Biologics ,Chunrui Li ,Equecabtagene Autoleucel ,Adimab Incyte ,Incyte Corporation ,Prnewswire Innovent Biologics Inc ,Huazhong University Of Science Technology ,Tongji Medical College ,International Myeloma Society ,China National Medical Products Administration ,Md Anderson Cancer Center ,Chinese Academy Of Medical Science Hematology Hospital ,Complete Response ,Abstract Code ,Myeloma Society ,Annual Meeting ,Refractory Multiple ,Chinese Academy ,Medical Science Hematology Hospital ,Tongji Hospital ,Huazhong University ,Sintilimab Injection ,Bevacizumab Injection ,Adalimumab Injection ,Rituximab Injection ,Pemigatinib Oral Inhibitor ,Ramucirumab Injection ,Selpercatinib Capsules ,Equecabtagene Autoleucel Injection ,Tafolecimab Injection ,Cancer Center ,Mainland China ,New Drug Application ,National Medical Products Administration ,